Lenalidomide does not increase AML progression risk in RBC transfusion-dependent patients with Low- or Intermediate-1-risk MDS with del(5q): a comparative analysis

Data comparing long-term outcomes in lenalidomide-treated and untreated patients with myelodysplastic syndromes (MDS) with del(5q) are limited. We evaluated clinical outcomes of 295 lenalidomide-treated patients from two clinical trials (MDS-003 and MDS-004) and 125 untreated red blood cell (RBC) tr...

Descripción completa

Detalles Bibliográficos
Autores principales: Kuendgen, A, Lauseker, M, List, A F, Fenaux, P, Giagounidis, A A, Brandenburg, N A, Backstrom, J, Glasmacher, A, Hasford, J, Germing, U
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group 2013
Materias:
Original Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3650492/
https://www.ncbi.nlm.nih.gov/pubmed/23257782
http://dx.doi.org/10.1038/leu.2012.369

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3650492/
https://www.ncbi.nlm.nih.gov/pubmed/23257782
http://dx.doi.org/10.1038/leu.2012.369

Ejemplares similares